EGFR and non-small cell lung carcinoma: For patients with advanced NSCLC and a positive EGFR gene drive, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the current first-line treatment option [3,4,5,6], but these lung cancer patients still have tumor recurrence and aggressive metastasis.